{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:11:36Z","timestamp":1784178696658,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013298","name":"Sociedad Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.reuma.2018.10.014","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T05:05:49Z","timestamp":1548565549000},"page":"315-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recomendaciones SER sobre la utilizaci\u00f3n de f\u00e1rmacos biol\u00f3gicos en el s\u00edndrome de Sj\u00f6gren primario"],"prefix":"10.1016","volume":"15","author":[{"given":"Jos\u00e9 Luis","family":"Andr\u00e9u S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Fern\u00e1ndez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra D\u00edaz","family":"del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Narv\u00e1ez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Rosas","family":"G\u00f3mez de Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rua-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Abad Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Noelia","family":"\u00c1lvarez Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier del Pino","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix Manuel","family":"Francisco Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gantes Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Gerardo","family":"Greco Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Vanesa","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Navarro Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Alberto Paz","family":"Solarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredeswinda I.","family":"Romero Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Sivera Mascar\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2018.10.014_bib0390","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.reuma.2018.10.014_bib0395","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12026-016-8844-4","article-title":"Primary Sjogren's syndrome: clinical phenotypes, outcome and the development of biomarkers","volume":"65","author":"Goules","year":"2017","journal-title":"Immunol Res."},{"key":"10.1016\/j.reuma.2018.10.014_bib0400","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.reuma.2018.10.014_bib0405","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sjogren's syndrome: A systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0410","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sjogren syndrome in Spain: Clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.10.014_bib0415","first-page":"184","article-title":"Sjogren SER: National registry of the Spanish Society of Rheumatology of patients with primary Sjogren syndrome: Objectives and methodology","volume":"12","author":"Fernandez Castro","year":"2016","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.10.014_bib0420","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0430","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/PPA.S132751","article-title":"Sjogren's syndrome is associated with negatively variable impacts on domains of health-related quality of life: Evidence from Short Form 36 questionnaire and a meta-analysis","volume":"11","author":"Zhang","year":"2017","journal-title":"Patient Prefer Adherence."},{"issue":"Suppl 2","key":"10.1016\/j.reuma.2018.10.014_bib0435","first-page":"1","article-title":"[Etiologic treatment of sicca syndrome. What can the rheumatologist offer?] [art\u00edculo en espa\u00f1ol]","volume":"6","author":"Fernandez Castro","year":"2010","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.10.014_bib0440","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","article-title":"Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome","volume":"38","author":"Miyawaki","year":"1999","journal-title":"Intern Med."},{"key":"10.1016\/j.reuma.2018.10.014_bib0445","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12891-017-1543-z","article-title":"Is hydroxychloroquine effective in treating primary Sjogren's syndrome: A systematic review and meta-analysis","volume":"18","author":"Wang","year":"2017","journal-title":"BMC Musculoskelet Disord."},{"key":"10.1016\/j.reuma.2018.10.014_bib0450","first-page":"555","article-title":"Methotrexate in primary Sjogren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0455","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sjogren's syndrome: A phase II pilot study","volume":"66","author":"Van Woerkom","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0460","first-page":"402","article-title":"Treatment of primary Sjogren's syndrome with D-penicillamine: A pilot study","volume":"60","author":"ter Borg","year":"2002","journal-title":"Neth J Med."},{"key":"10.1016\/j.reuma.2018.10.014_bib0465","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0470","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin A (CyA) in primary Sjogren's syndrome: A double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0475","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0480","doi-asserted-by":"crossref","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sjogren syndrome: A pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.10.014_bib0485","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.semarthrit.2015.06.007","article-title":"Advances in the treatment of ocular dryness associated with Sjogrens syndrome","volume":"45","author":"Ciurtin","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0490","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtos.2014.12.001","article-title":"Clinical guidelines for management of dry eye associated with Sjogren disease","volume":"13","author":"Foulks","year":"2015","journal-title":"Ocul Surf."},{"key":"10.1016\/j.reuma.2018.10.014_bib0495","first-page":"387","article-title":"Oral involvement in patients with primary Sjogren's syndrome. Multidisciplinary care by dentists and rheumatologists","volume":"11","author":"Lopez-Pintor","year":"2015","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.10.014_bib0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sjogren's syndrome: A systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reuma.2018.10.014_bib0505","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sjogren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients","volume":"75","author":"Brito-Zeron","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0510","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","article-title":"Innate immunity in Sjogren's syndrome","volume":"182","author":"Kiripolsky","year":"2017","journal-title":"Clin Immunol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0515","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0520","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren's syndrome: A pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0525","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0530","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: A pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0535","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren's syndrome: One-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0540","first-page":"814","article-title":"Notice of retraction of two articles (\u00abInfliximab in patients with primary Sjogren's syndrome: A pilot study\u00bb and \u00abInfliximab in patients with primary Sjogren's syndrome: One-year followup\u00bb)","volume":"65","author":"Steinfeld","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0545","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","article-title":"B cells in Sjogren's syndrome: From pathophysiology to diagnosis and treatment","volume":"39","author":"Cornec","year":"2012","journal-title":"J Autoimmun."},{"key":"10.1016\/j.reuma.2018.10.014_bib0550","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.13192","article-title":"Sjogren Syndrome-associated lymphomas: An update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150749","article-title":"Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): Systematic review and meta-analysis","volume":"11","author":"Souza","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.reuma.2018.10.014_bib0560","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0565","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: A randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.reuma.2018.10.014_bib0570","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0575","doi-asserted-by":"crossref","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: A prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.10.014_bib0580","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0585","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0590","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: Results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0595","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: Results in 78 patients of the autoimmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0600","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and safety of biological DMARDs modulating B cells in primary Sjogren's syndrome: Systematic review and meta-analysis","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.reuma.2018.10.014_bib0605","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0610","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: Results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0615","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0620","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2018.10.014_bib0625","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1874312900802010038","article-title":"Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma","volume":"2","author":"Quartuccio","year":"2008","journal-title":"Open Rheumatol J."},{"key":"10.1016\/j.reuma.2018.10.014_bib0630","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.10.014_bib0635","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2018.10.014_bib0640","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: Results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0645","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: The BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2018.10.014_bib0650","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: Follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0655","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjogren's syndrome: Results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.10.014_bib0660","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-3083.1999.00533.x","article-title":"Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome","volume":"49","author":"Halse","year":"1999","journal-title":"Scand J Immunol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0665","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002960050070","article-title":"Increased salivary interleukin-6 levels in patients with primary Sjogren's syndrome","volume":"18","author":"Tishler","year":"1999","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reuma.2018.10.014_bib0670","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","article-title":"Elevated tear interleukin-6 levels in patients with Sjogren syndrome","volume":"105","author":"Tishler","year":"1998","journal-title":"Ophthalmology."},{"key":"10.1016\/j.reuma.2018.10.014_bib0675","first-page":"1089","article-title":"Salivary and serum interleukin 6 in primary Sjogren's syndrome","volume":"24","author":"Grisius","year":"1997","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0680","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/40.6.656","article-title":"Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease","volume":"40","author":"Hulkkonen","year":"2001","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2018.10.014_bib0685","doi-asserted-by":"crossref","DOI":"10.1186\/ar3220","article-title":"Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survival","volume":"13","author":"Szyszko","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.10.014_bib0690","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10384-011-0002-x","article-title":"Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface","volume":"55","author":"Sugaya","year":"2011","journal-title":"Jpn J Ophthalmol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0695","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0394632016651273","article-title":"A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjogren's syndrome","volume":"29","author":"Benchabane","year":"2016","journal-title":"Int J Immunopathol Pharmacol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0700","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0705","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: A pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2018.10.014_bib0710","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3899\/jrheum.160459","article-title":"Detailed analysis of the articular domain in patients with primary Sjogren syndrome","volume":"44","author":"Moerman","year":"2017","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0715","unstructured":"A study to assess the efficacy and safety of abatacept in adults with active primary. Sjogren's syndrome [consultado 28 Dic 2017]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02915159"},{"key":"10.1016\/j.reuma.2018.10.014_bib0720","unstructured":"Randomized D-b, placebo-controlled phase III study to assess the efficacy and safety of abatacept in patients with primary Sj\u00f6gren's syndrome (ASAP III Study, Abatacept Sj\u00f6gren Active Patients Phase III Study) [consultado 28 Dic 2017]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02067910"},{"key":"10.1016\/j.reuma.2018.10.014_bib0725","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-209076","article-title":"Tocilizumab for refractory organising pneumonia associated with Sjogren's disease","author":"Justet","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.reuma.2018.10.014_bib0730","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report","volume":"26","author":"Komai","year":"2016","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.reuma.2018.10.014_bib0735","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): Development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0740","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/annrheumdis-2016-210448","article-title":"Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren's syndrome","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0745","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2012.08.001","article-title":"Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: A systematic review","volume":"12","author":"Guellec","year":"2013","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.reuma.2018.10.014_bib0750","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.10.014_bib0755","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf."},{"key":"10.1016\/j.reuma.2018.10.014_bib0760","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000443","article-title":"Patient burden of Sjogren's: A comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity","volume":"3","author":"Hammitt","year":"2017","journal-title":"RMD Open."},{"key":"10.1016\/j.reuma.2018.10.014_bib0765","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sjogren's syndrome disease activity index (ESSDAI): A user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open."},{"key":"10.1016\/j.reuma.2018.10.014_bib0770","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X18302602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X18302602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:58:29Z","timestamp":1761663509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X18302602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1699258X18302602"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2018.10.014","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones SER sobre la utilizaci\u00f3n de f\u00e1rmacos biol\u00f3gicos en el s\u00edndrome de Sj\u00f6gren primario","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2018.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}